MedPath

Biomarkers for fatigue in patients with Myasthenia Gravis

Recruiting
Conditions
cognitieve vermoeidheid
Myasthenia Gravis
10029317
Registration Number
NL-OMON55325
Lead Sponsor
eids Universitair Medisch Centrum
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Not specified
Target Recruitment
115
Inclusion Criteria

myasthenia gravis with anti-acetyl choline receptor antibodies

Exclusion Criteria

- A medical history of other active auto-immune disorders for which the patient
currently receives a medical treatment, such as thyroid disease or rheumatoid
arthritis.
- A recent medical history of neoplasms.
- Substance abuse.

Study & Design

Study Type
Observational invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>The main study parameter is a serum biomarker which correlates with levels of<br /><br>fatigue. We expect this biomarkers to be (partly) influenced by disease<br /><br>severity and treatment. Therefore this study has the option to include a<br /><br>longitudinal design (part II) with data and samples over the course of 6-12<br /><br>months (2 visits). During this part II of the study fluctuations in fatigue<br /><br>will be related to fluctuations in the previously identified biomarkers.</p><br>
Secondary Outcome Measures
NameTimeMethod
<p>We will collect information on depression scores, age, sex, BMI, medication and<br /><br>degree of physical activity as these factors are associated with fatigue and<br /><br>are likely to influence results. </p><br>
© Copyright 2025. All Rights Reserved by MedPath